Pan-tumor Activity of Olomorasib (LY3537982), a Second-Generation KRAS G12C Inhibitor (g12ci), in Patients with KRAS G12C-mutant Advanced Solid Tumors.
JOURNAL OF CLINICAL ONCOLOGY(2024)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined